MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6360
-0.0240
-3.64%
Closed 16:00 01/24 EST
OPEN
0.6652
PREV CLOSE
0.6600
HIGH
0.6734
LOW
0.6300
VOLUME
233.53K
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.4900
MARKET CAP
28.80M
P/E (TTM)
-0.4408
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APVO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

APVO News

  • Aptevo Therapeutics' APVO436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking BEAT AML(R) Master Clinical Trial
  • ACCESSWIRE.01/13 13:00
  • Aptevo Therapeutics Inc. (APVO): Are Hedge Funds Right About This Stock?
  • Insider Monkey.12/19/2019 20:50
  • Aptevo Therapeutics Reports Receives Orphan Drug Designation For APVO436 For Treatment Of Acute Myelogenous Leukemia
  • Benzinga.12/06/2019 14:01
  • Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
  • GlobeNewswire.12/06/2019 14:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About APVO

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).
More

Webull offers Aptevo Therapeutics Inc (APVO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.